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mation rarely influences a physician's practice. Clinicians don't know if their patients are being adherent to the medications they prescribe. We have shown that at least some of the time, flying blind likely confuses physicians into thinking that poor adherence represents a lack of medication efficacy. And this leads doctors to move on to the next, and often more expensive, option."
Is Technology the Answer to This?
A survey published in September 2017 by Medscape (http://wb.md/2y1Wte3) suggests there is still some way to go, particularly with patient adoption of EHR/ patient-portal use-more than two-thirds of practices offering patient portals report that only a quarter of their patients actually log in.
But when physicians were asked about how they use their EHRs (besides documenting a patient visit), half reportedly used it to identify patients requiring a follow-up visit, and 42% used it "to identify patients who need additional treatments." Presumably, if that last figure is indeed reflective of EHR usage, leveraging these systems to improve drug adherence is going to take quite some work. That's not the worst of it; 12% of self-employed and 4% of employed physicians reportedly don't have an EHR at all.
About Skipping Breakfast
Skipping breakfast apparently does influence glycemic responses after lunch, according to Jakubowicz et al. (Diabetes Care http://doi.org/cdgt). As a result, they now suggest that consuming breakfast might well be an important strategy to control glycemia in the very short term in type 2 diabetes. And according to the authors, the effect seems to be related to the circadian clock.
The cross-over study randomly assigned both healthy individuals and those with type 2 diabetes to two test days, one with and one without breakfast. Then, with regular blood samples throughout the day, the researchers measured various circadian clock-related gene expression markers, plus blood glucose, insulin, glucagon-like peptide 1 (GLP-1), and a range of other blood markers.
They say that skipping breakfast did alter gene expression in both groups, but that the glucose excursion was The ADA Call Center, 1-800-DIABETES, responded to hundreds of calls for help, and staff, volunteers, and coalition partners reached out to program participants, camp families, and donors to ensure that affected communities had access to the supplies and resources they needed. A hotline, 1-314-INSULIN, was also set up for health care providers from affected areas who were in need of diabetes supplies. In addition, the ADA website (diabetes.org) posted and regularly updated lists of resources and information specific to affected areas, as well as links for people wishing to donate diabetes supplies or money to the relief effort.
Help your patients with diabetes prepare for future natural disasters by checking out the following links on the ADA website:
• Diabetes tips for first responders (http://bit.ly/2ymeY9e)
• Information on how to care for yourself or a loved one with diabetes during an emergency situation (http://bit. ly/2yBm5eZ)
• Meanwhile another genome-wide association study by Zhao et al. (Nature Genetics, http://doi.org/gbt4cb), again involving many thousands of individuals, has identified a whole series of genetic signals linked to type 2 diabetes and, in some cases, also coronary heart disease. As a result, they say the findings likely indicate that there are biological pathways that are shared between the diseases and that would point toward there being potential targets for therapy that target both diseases at the same time. Author Benjamin Voight said in an institutional press release (http://bit.ly/2xuLp60), "I'm hopeful that with the advanced genomic engineering techniques now available, we'll be able to quickly convert our human genetics observations into concrete details regarding the molecular mechanisms involved in both heart disease and diabetes."
Translating apparent genetic associations with diseases into drug targets can be an intricate task, although it can be done. Mercader et al., (Diabetes, http://doi.org/ cdgv) detail one such effort, first identifying that a variant in the gene that encodes insulin-like growth factor 2 is likely associated with a reduction in type 2 diabetes risk of ~20%. With a series of follow-up experiments, they then detail how the likely mechanisms affect risk of the disease. On that basis, they say reducing the expression of isoform 2 of the gene in certain tissues could potentially be achieved pharmacologically.
Author Jose Florez told Diabetes: "Finding a genetic association is only the first step toward elucidating molecular mechanism and direction of effect, both of which we have pursued here to begin translating genetics into therapeutics."
PROGRESSION OF AND FDA APPROVAL FOR ARTIFICIAL PANCREAS TECHNOLOGY
Tandem Diabetes Care, Inc., has announced (http://bit.ly/2wieL79) that it has received approval from the U.S. Food and Drug Administration (FDA; http://bit.ly/2xEEM37) for a tie-up between its t:slim X2™ insulin infusion pump and Dexcom's G5 mobile continuous glucose monitoring (CGM) system. The combination is now reportedly approved for use by children ≥6 years of age, a drop from an age limit of 12 years on previous models. The system also received approval to let users make treatment decisions without first needing to use a fingerprick test to determine blood glucose (although fingerpricks are still needed for calibration). Users can reportedly view the CGM data on the pump's screen, as well as in a smartphone app (which we imagine will be a huge win for patients and also parents of children with type 1 diabetes).
Although the system is not a fully automated insulin delivery device yet, the update pathway promised from the manufacturers seems to suggest it will be possible to upgrade once research is complete and approvals are granted. A pivotal trial (http://bit.ly/2hs0vVS) is ongoing with the system, which crucially includes the company's "predictive low glucose suspend" feature that is designed to predict hypoglycemia and take automated action to prevent it. The trial has a primary completion date of November 2017. Pending trial success and FDA approval, Tandem said in statements that it aims to launch new version(s) of the system in mid-2018. is not the case now, and they detail the performance of one particular system on the ski slopes.
They report a trial of a closed-loop control (CLC) system during a prolonged skiing camp attended by teenaged type 1 diabetes patients. They reveal that improved glycemic control and reduced exposure to hypoglycemia is possible even during prolonged exercise, at high altitude, and during exposure to cold temperatures.
According to the authors, the randomized trial involved 32 adolescents with type 1 diabetes who attended a 5-day skiing camp at two sites in Virginia and Colorado. They compared the performance of the CLC system against an open-loop, physicianmonitored system (the control).
They report that, after the daily sessions of skiing/ snowboarding and evening activities, the CLC system managed to maintain overall blood glucose levels between 70 and 180 mg/dL about 71% of the time. In comparison, the control system only managed to be in range about 65% of the time. Throughout the day, the percentage time in range varied, but the maximum effect was seen late at night. There were no adverse events associated with the interventions (there were a few broken bones; it is skiing, after all), and reportedly, feedback from participants was overwhelmingly positive. Both the authors and a separate editorial (http://doi. org/cdg2) suggest that the results might influence prescribing decisions and that the drug is likely safe and effective in the population studied. However, the editorial highlights that costs and access to the drug might preclude its widespread use in a number of countries.
IRIS Trial: Secondary Analysis Suggests That Diabetes Drug Pioglitazone Might Benefit High-Risk Stroke Patients
A secondary analysis of the IRIS (Insulin Resistance Intervention After Stroke) trial suggests that stroke patients with insulin resistance but not diabetes at high 5-year risk for having another stroke or myocardial infarction might benefit from the diabetes drug pioglitazone.
According to the analysis by Kernan et al. in JAMA Neurology (http://doi.org/cfqq), the absolute risk difference of 4.9% between high-and low-risk patients suggests that high-risk patients may derive benefit from the drug. However, the authors caution that this comes with an increased risk of bone fractures. As a result, they suggest that their results might help clinicians talk with patients about the likely benefits and harms of the therapy.
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TOSCA.IT: Pioglitazone in Head-to-Head Trial With Sulfonylurea Is No Better for Heart Outcomes
In the pragmatic, randomized TOSCA.IT (Thiazolidinediones or Sulfonylureas and Cardiovascular Accidents Intervention Trial), pioglitazone as an add-on to metformin was apparently similar to sulfonylurea (mostly glimepiride and gliclazide) as a metformin add-on for a primary composite outcome of all-cause mortality and various nonfatal heart outcomes in type 2 diabetes. In a simultaneously published article in The Lancet Diabetes and Endocrinology (http:// doi.org/cdg5), authors Vaccaro et al.
wrote: "Both of these widely available and affordable treatments are suitable options with respect to efficacy and adverse events, although pioglitazone was associated with fewer hypoglycemia events."
ACE: Acarbose Delays Diabetes Onset but Fails to Reduce Cardiovascular Events
Acarbose, an α-glucosidase inhibitor that was tipped as an antidiabetes drug targeting postprandial hyperglycemia, has failed to improve composite cardiovascular outcomes in patients with coronary heart disease and impaired glucose tolerance in the ACE (Acarbose Cardiovascular Evaluation) trial. However, it can apparently reduce progression to type 2 diabetes, according to Holman et al., who presented their results at the EASD meeting and simultaneously published them in The Lancet Diabetes and Endocrinology (http:// doi.org/cdg6). They wrote: "On the basis of the data from this trial and the NAVIGATOR study, it seems that, despite the strong epidemiological data linking postprandial In separate studies reported at the conference, elevated salt intake has been tied to increased risk of type 2 diabetes (http://bit.ly/2ynXhWK), while sugar substitutes that are often used in diet beverages might play havoc with glycemic
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